These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 7519363

  • 1. Prostate specific antigen progression rates after radical prostatectomy or radiation therapy for localized prostate cancer.
    Fowler JE, Pandey P, Braswell NT, Seaver L.
    Surgery; 1994 Aug; 116(2):302-5; discussion 305-6. PubMed ID: 7519363
    [Abstract] [Full Text] [Related]

  • 2. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
    Soergel TM, Koch MO, Foster RS, Bihrle R, Wahle G, Gardner T, Jung SH.
    J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
    [Abstract] [Full Text] [Related]

  • 3. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P, Katcher J, Levin H, Zippe C, Suh J, Macklis R, Klein E.
    Cancer J Sci Am; 1997 Dec; 3(2):78-87. PubMed ID: 9099457
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
    Pruthi RS, Derksen JE, Moore D, Carson CC, Grigson G, Watkins C, Wallen E.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2172-7. PubMed ID: 16609031
    [Abstract] [Full Text] [Related]

  • 5. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer.
    Pruthi RS, Johnstone I, Tu IP, Stamey TA.
    Urology; 1997 May 01; 49(5):737-42. PubMed ID: 9145980
    [Abstract] [Full Text] [Related]

  • 6. Prostate specific antigen doubling time after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy.
    Rabbani F, Perrotti M, Bastar A, Fair WR.
    J Urol; 1999 Mar 01; 161(3):847-52. PubMed ID: 10022699
    [Abstract] [Full Text] [Related]

  • 7. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P, Katcher J, Levin H, Zippe C, Klein E.
    Urology; 1996 Aug 01; 48(2):249-60. PubMed ID: 8753737
    [Abstract] [Full Text] [Related]

  • 8. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer.
    Amling CL, Lerner SE, Martin SK, Slezak JM, Blute ML, Zincke H.
    J Urol; 1999 Mar 01; 161(3):857-62; discussion 862-3. PubMed ID: 10022701
    [Abstract] [Full Text] [Related]

  • 9. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome.
    Zagars GK, Pollack A.
    Urology; 1995 Mar 01; 45(3):476-83. PubMed ID: 7533459
    [Abstract] [Full Text] [Related]

  • 10. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
    D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP.
    Cancer; 2002 Jul 15; 95(2):281-6. PubMed ID: 12124827
    [Abstract] [Full Text] [Related]

  • 11. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy.
    Schild SE, Buskirk SJ, Wong WW, Halyard MY, Swanson SK, Novicki DE, Ferrigni RG.
    J Urol; 1996 Nov 15; 156(5):1725-9. PubMed ID: 8863580
    [Abstract] [Full Text] [Related]

  • 12. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.
    Do T, Parker RG, Do C, Tran L, Do L, Dolkar D.
    Cancer J Sci Am; 1998 Nov 15; 4(5):324-30. PubMed ID: 9815297
    [Abstract] [Full Text] [Related]

  • 13. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M, Hayasaka S, Taylor JM, Shah R, Proverbs-Singh T, Manley S, Rubin MA.
    J Urol; 2001 Dec 15; 166(6):2193-7. PubMed ID: 11696734
    [Abstract] [Full Text] [Related]

  • 14. Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer.
    D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Richie JP.
    Mol Urol; 2000 Dec 15; 4(3):171-5;discussion 177. PubMed ID: 11062371
    [Abstract] [Full Text] [Related]

  • 15. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK, Levy LB, Cheung R, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):456-62. PubMed ID: 15927415
    [Abstract] [Full Text] [Related]

  • 16. Prostate-specific antigen (PSA) in the monitoring of prostate cancer after radical prostatectomy and external beam radiation.
    Schaefer U, Witt F, Schueller P, Micke O, Willich N.
    Anticancer Res; 2000 Oct 01; 20(6D):4989-92. PubMed ID: 11326654
    [Abstract] [Full Text] [Related]

  • 17. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
    Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Palisaar J, Huland E, Scardino PT, Kattan MW, Huland H.
    J Urol; 2002 Mar 01; 167(3):1306-9. PubMed ID: 11832719
    [Abstract] [Full Text] [Related]

  • 18. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
    Shariat SF, Abdel-Aziz KF, Roehrborn CG, Lotan Y.
    Eur Urol; 2006 Feb 01; 49(2):293-302. PubMed ID: 16387412
    [Abstract] [Full Text] [Related]

  • 19. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA.
    Int J Radiat Oncol Biol Phys; 2005 Mar 01; 61(3):714-24. PubMed ID: 15708249
    [Abstract] [Full Text] [Related]

  • 20. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels.
    Rogers E, Ohori M, Kassabian VS, Wheeler TM, Scardino PT.
    J Urol; 1995 Jan 01; 153(1):104-10. PubMed ID: 7526002
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.